Clinical Trials

ARDA Multifocal Motor Neuropathy Study The ARDA study is designed to assess the safety and effectiveness of the investigational study drug compared to a placebo for the treatment of adults living with MMN. Participants enrolled in the study will be randomly assigned by a computer to either receive the investigational drug or a placebo. Participants…

International Guillain-Barré Syndrome Outcome Study (IGOS) The international GBS Outcome Study (IGOS) is the largest and longest prospective trial designed to collect extensive data from patients afflicted with GBS in a systematic manner. The aim is to collect information from patients by intensive international collaboration. All patients are followed at standard intervals from the earliest…

A Clinical Study of ANX005 and IVIG in Subjects with Guillain Barré Syndrome (GBS) A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects With Guillain Barré Syndrome CLICK HERE FOR MORE INFORMATION ON THE CURRENT TRIAL VIA CLINICALTRIALS.GOV

Open-Label Phase 2 study with SAR445088, a Complement C1s inhibitor, in adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), sponsored by Sanofi This global multicenter study will evaluate the efficacy, safety and tolerability of SAR445088 in CIDP. SAR445088 (previously known as BIVV020) is an investigational monoclonal antibody that targets Complement C1s and has a subcutaneous route…

Randomized Study of Single vs. Multiple Privigen Dose Regimens in Pediatric CIDP CSL Behring is conducting an open-label study to investigate the efficacy of single and multiple-dose Privigen administration in IVIG‑pretreated and IVIG-untreated pediatric subjects with chronic inflammatory demyelinating polyneuropathy (CIDP). ClinicalTrials.gov Identifier: NCT03684018 CLICK HERE FOR MORE INFORMATION ON THE CURRENT TRIAL VIA CLINICALTRIALS.GOV

A Study to Assess the Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder that Affects the Peripheral Nerves) (ADHERE) *No Longer Recruiting* This is a phase 2 study to evaluate the safety and efficacy of the subcutaneous formulation of efgartigimod in adults with…

Have you been diagnosed with CIDP? A clinical research study (ARISE) is now enrolling to evaluate an investigational medication. Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare disease where thebody’s natural defenses, like antibodies, attack the covering of the nerves, called myelin,and damage nerve function. While symptoms aren’t the same for everyone, CIDP canmake your…